Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RAPT Stock Forecast 2026-2027
$58.01
Current Price
$1.68B
Market Cap
Buy 0
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to RAPT Price Targets
0.0%
To High Target of $58.00
0.0%
To Median Target of $58.00
0.0%
To Low Target of $58.00
RAPT Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+467.1%
1 Year Change
+71.3%
Year-to-Date Change
0.0%
From 52W High of $58.01
+924.1%
From 52W Low of $5.66
📊 TOP ANALYST CALLS
Did RAPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if RAPT Therapeutics is one of their latest high-conviction picks.
Latest RAPT Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, RAPT has a neutral consensus with a median price target of $58.00 (ranging from $58.00 to $58.00). The overall analyst rating is Buy (6.0/10). Currently trading at $58.01, the median forecast implies a 0.0% downside. This outlook is supported by 0 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Etzer Darout at Barclays, projecting a 0.0% downside. Conversely, the most conservative target is provided by Etzer Darout at Barclays, suggesting a 0.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RAPT Analyst Ratings
0
Buy
4
Hold
0
Sell
RAPT Price Target Range
Low
$58.00
Average
$58.00
High
$58.00
Current: $58.01
Latest RAPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RAPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 21, 2026 | Barclays | Etzer Darout | Equal-Weight | Downgrade | $58.00 |
| Jan 21, 2026 | Leerink Partners | Thomas Smith | Market Perform | Downgrade | $58.00 |
| Jan 20, 2026 | HC Wainwright & Co. | Emily Bodnar | Neutral | Downgrade | $58.00 |
| Jan 20, 2026 | LifeSci Capital | Market Perform | Downgrade | $N/A | |
| Jan 20, 2026 | Wells Fargo | Yanan Zhu | Equal-Weight | Downgrade | $58.00 |
| Jan 20, 2026 | Clear Street | Kaveri Pohlman | Hold | Downgrade | $58.00 |
| Jan 20, 2026 | TD Cowen | Yaron Werber | Hold | Downgrade | $N/A |
| Dec 18, 2025 | TD Cowen | Yaron Werber | Buy | Initiates | $N/A |
| Nov 12, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $57.00 |
| Nov 7, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $56.00 |
| Nov 3, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $72.00 |
| Oct 27, 2025 | Guggenheim | Yatin Suneja | Buy | Initiates | $70.00 |
| Oct 27, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $72.00 |
| Oct 21, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $58.00 |
| Oct 21, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $48.00 |
| Oct 21, 2025 | Clear Street | Kaveri Pohlman | Buy | Maintains | $60.00 |
| Oct 20, 2025 | JP Morgan | Anupam Rama | Overweight | Upgrade | $55.00 |
| Oct 13, 2025 | Barclays | Etzer Darout | Overweight | Initiates | $35.00 |
| Sep 30, 2025 | Clear Street | Kaveri Pohlman | Buy | Maintains | $41.00 |
| Sep 26, 2025 | Leerink Partners | Thomas Smith | Outperform | Upgrade | $37.00 |
Rapt Therapeutics, Inc. (RAPT) Competitors
The following stocks are similar to RAPT Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RAPT
RAPT Therapeutics
mkt cap
1.68B
Rapt Therapeutics, Inc. (RAPT) Financial Data
Rapt Therapeutics, Inc. has a market capitalization of $1.68B with a P/E ratio of -2.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -85.4%.
Valuation Metrics
Market Cap
$1.68B
Enterprise Value
$1.45B
P/E Ratio
-2.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.8%
Current Ratio
12.0x
Debt/Equity
1.7x
ROE
-85.4%
ROA
-51.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rapt Therapeutics, Inc. (RAPT) Business Model
About Rapt Therapeutics, Inc.
What They Do
Develops therapies for inflammatory and immunologic diseases.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, focusing on discovering and developing novel therapies for inflammatory and immunologic diseases. It generates revenue through the development and eventual commercialization of its proprietary drug candidates, such as ozureprubart, which is currently in phase IIb clinical trials.
Additional Information
Founded in 2015 and based in South San Francisco, California, Rapt Therapeutics is addressing significant unmet medical needs in the allergy and immunology space, particularly for severe allergic reactions. Its innovative approach aims to improve patient outcomes by offering therapies that require less frequent dosing and target critical immune responses.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
60
CEO
Dr. Brian Russell Wong M.D., Ph.D.
Country
United States
IPO Year
N/A
Website
www.rapt.comRapt Therapeutics, Inc. (RAPT) Latest News & Analysis
Latest News
Quick Summary
FCPM III Services acquired 1,489,096 RAPT shares last quarter, increasing the position's value by $53.22 million due to trading and stock price changes.
Why It Matters
FCPM III Services' significant share acquisition and the rise in position value indicate strong confidence in RAPT, potentially signaling growth and attracting investor interest.
Source: The Motley Fool
Market Sentiment:
Positive
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
4 months ago
Quick Summary
OrbiMed Advisors boosted its stake in RAPT Therapeutics by 556,273 shares in Q4, totaling $17.28 million. The value of the stake increased by $27.62 million due to share price appreciation.
Why It Matters
OrbiMed's significant investment in RAPT Therapeutics signals confidence in the company's growth potential, likely influencing market perceptions and stock performance.
Source: The Motley Fool
Market Sentiment:
Positive
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
4 months ago
Quick Summary
Great Point Partners acquired 581,187 shares of RAPT Therapeutics in Q4, increasing the position's value by $19.68 million at quarter-end.
Why It Matters
Great Point Partners' acquisition of RAPT Therapeutics shares indicates institutional confidence, potentially signaling future growth and impacting stock performance positively.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Kahn Swick & Foti is investigating the proposed sale of RAPT Therapeutics to GSK, where RAPT shareholders would receive $58 per share. They aim to assess the adequacy of this offer.
Why It Matters
The investigation into RAPT's sale to GSK could affect the deal's valuation and shareholder satisfaction, influencing RAPT's stock price and GSK's acquisition strategy.
Source: Business Wire
Market Sentiment:
Neutral
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
5 months ago
Quick Summary
Shareholders are advised to contact the firm promptly due to potential time constraints on enforcing their rights.
Why It Matters
Limited time for shareholders to enforce rights could signal potential legal issues or corporate governance changes, impacting stock value and investor confidence. Prompt action may be necessary.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
GSK has agreed to acquire RAPT Therapeutics for $2.2 billion, enhancing its respiratory and immunology portfolio with the addition of ozureprubart.
Why It Matters
GSK’s acquisition of RAPT Therapeutics enhances its pipeline and portfolio, potentially boosting future revenues and market position in respiratory and immunology sectors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About RAPT Stock
What is Rapt Therapeutics, Inc.'s (RAPT) stock forecast for 2027?
Based on our analysis of 21 Wall Street analysts, Rapt Therapeutics, Inc. (RAPT) has a median price target of $58.00. The highest price target is $58.00 and the lowest is $58.00.
Is RAPT stock a good investment in 2027?
According to current analyst ratings, RAPT has 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $58.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RAPT stock?
Wall Street analysts predict RAPT stock could reach $58.00 in the next 12 months. This represents a 0.0% decrease from the current price of $58.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rapt Therapeutics, Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, focusing on discovering and developing novel therapies for inflammatory and immunologic diseases. It generates revenue through the development and eventual commercialization of its proprietary drug candidates, such as ozureprubart, which is currently in phase IIb clinical trials.
What is the highest forecasted price for RAPT Rapt Therapeutics, Inc.?
The highest price target for RAPT is $58.00 from Etzer Darout at Barclays, which represents a 0.0% decrease from the current price of $58.01.
What is the lowest forecasted price for RAPT Rapt Therapeutics, Inc.?
The lowest price target for RAPT is $58.00 from Etzer Darout at Barclays, which represents a 0.0% decrease from the current price of $58.01.
What is the overall RAPT consensus from analysts for Rapt Therapeutics, Inc.?
The overall analyst consensus for RAPT is neutral. Out of 21 Wall Street analysts, 0 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $58.00.
How accurate are RAPT stock price projections?
Stock price projections, including those for Rapt Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:25 PM UTC